https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=9727
https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=9727
No pharmaceutical opinion available for this interaction.
Elvitegravir / Cobicistat may inhibit hepatic transports OATP1B1/B3 and BCRP and increase plasma concentration of Rosuvastatin.
–
–
–
Probably without any clinical consequence.
No a priori dosage adjustment is recommended.
Monitor for adverse effects.
See comments.
–
–
–
| Reference number |
|---|
| # patients |
| HIV |
| Dose |
| Frequency |
| AUC |
| Cmin |
| Cmax |
| 3360 |
|---|
| 10 |
| - |
| 150/150 mg |
| QD |
| + 2% |
| - 2% |
| - 6% |
| 3360 |
|---|
| 10 |
| - |
| 10 mg |
| x 1 |
| + 38% |
| + 43% |
| + 89% |
Ref #3360, 2570 and 3281 : The increase in AUC ranged from 48-142% and the increase in AUC ranged from 13-67% depending on the subject under study.
Likely driven by inhibition of intestinal efflux by BCRP or hepatic uptake by OATPs by EVG/c. No serious adverse events or grade 2, 3 or 4 AEs or grade 3 or 4 laboratory abnormalities occurred.
The study used as a reference a concentration of rosuvastatin alone with the equivalence limits of 70-143% for AUC and 70-175% for Cmax.
The modest increase observed is considered clinically insignificant. Elvitegravir/cobicistat can be taken with rosuvastatin.